Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JYLAMVO vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Treatment of severe, active rheumatoid arthritis in adults,Treatment of polyarticular-course juvenile idiopathic arthritis in children,Treatment of severe psoriasis in adults
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
Methotrexate is primarily metabolized in the liver to polyglutamated forms, which are retained intracellularly. It undergoes hepatic metabolism via aldehyde oxidase and xanthine oxidase. Renal excretion is the major elimination route.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
Approximately 85-90% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 20–30% bound to plasma proteins.
Volume of distribution is 0.6-1.2 L/kg, indicating distribution into total body water and some tissue binding.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Oral bioavailability is 60-75% due to first-pass metabolism; absolute bioavailability is 70%.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
No dose adjustment is recommended for patients with mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl 15-29 m L/min), reduce dose to 20 mg twice daily. For end-stage renal disease (Cr Cl <15 m L/min) or on dialysis, not recommended due to lack of data.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
For patients with mild hepatic impairment (Child-Pugh A), no dose adjustment. For moderate hepatic impairment (Child-Pugh B), reduce dose to 20 mg twice daily. For severe hepatic impairment (Child-Pugh C), not recommended.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and efficacy in pediatric patients have not been established; no recommended dosage.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment required based on age alone; monitor for increased risk of adverse events (e.g., myelosuppression, infections) as elderly patients may have decreased organ function and comorbidities.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
JYLAMVO can cause severe or fatal toxicities including hepatotoxicity, myelosuppression, pulmonary fibrosis, and renal failure. It is contraindicated in pregnancy (teratogenic) and in nursing mothers. Fatal toxicity has been reported with concomitant NSAID use. Monitoring for toxicity and appropriate dosing adjustments are required.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Hepatotoxicity (monitor liver function), myelosuppression (monitor CBC), pulmonary toxicity (interstitial pneumonitis), renal toxicity (monitor renal function), gastrointestinal toxicity, neurotoxicity, infections, and tumor lysis syndrome. Corticosteroids or other immunosuppressants may increase risk of infection.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Hypersensitivity to methotrexate, severe hepatic impairment, severe renal impairment, severe anemia, leukopenia, thrombocytopenia, pregnancy, breastfeeding, alcoholism, pre-existing immunodeficiency syndromes, and concurrent use of NSAIDs in patients with renal impairment.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No specific food interactions are known. Administer without regard to meals. Maintain adequate hydration.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
JYLAMVO (methotrexate) is contraindicated in pregnancy. It is an abortifacient and teratogen. First trimester exposure causes multiple congenital anomalies (craniofacial, limb, CNS defects) and spontaneous abortion. Second and third trimester use may cause fetal growth restriction, developmental delay, and potential methotrexate syndrome. Use effective contraception during and for at least 3 months after treatment.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
Contraindicated during breastfeeding. Methotrexate is excreted into breast milk in low concentrations (M/P ratio 0.6-1.1), but due to potential for serious adverse effects (immunosuppression, neutropenia, developmental toxicity) in the nursing infant, breastfeeding is not recommended. Discontinue breastfeeding or avoid JYLAMVO.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
Not applicable. JYLAMVO is contraindicated in pregnancy. No dose adjustments exist as it should not be used during pregnancy. Discontinue immediately if pregnancy occurs.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
JYLAMVO (amivantamab) is a bispecific EGFR-MET antibody for EGFR exon 20 insertion mutation-positive NSCLC. Monitor for infusion-related reactions (premedicate with antihistamines, antipyretics, and corticosteroids). Assess for interstitial lung disease (ILD) prior to each dose; withhold for suspected ILD. Check serum albumin and electrolytes before treatment; hypoalbuminemia increases risk of toxicities. Advise use of sunscreen and sun protective measures due to photosensitivity risk.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
JYLAMVO is given as an intravenous infusion over 2-4 hours, typically every 2 weeks after an initial loading dose.,You may experience infusion reactions; symptoms include fever, chills, nausea, or shortness of breath. Tell your nurse immediately if these occur.,This drug can cause lung inflammation (ILD); report any new or worsening cough, chest pain, or difficulty breathing.,Avoid prolonged sun exposure; use broad-spectrum sunscreen (SPF 30+) and wear protective clothing.,Your doctor will monitor your blood counts and kidney function regularly during treatment.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JYLAMVO vs CLADRIBINE, answered by our medical review team.
JYLAMVO is a Antineoplastic Agent that works by JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JYLAMVO and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JYLAMVO is: Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JYLAMVO and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JYLAMVO is classified as Category C. JYLAMVO (methotrexate) is contraindicated in pregnancy. It is an abortifacient and teratogen. First trimester exposure causes multiple congenital anomalies (craniofacial, limb, CNS. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.